MedTrace Logo

Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in HCC

NCT06461936 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 620

Last updated 2024-06-17

No results posted yet for this study

Summary

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC positive patients have a higher rate of postoperative recurrence. However, it is not clear how the surgical prognosis of VETC-positive patients can be improved.

Conditions

  • HCC
  • Adjuvant Therapy
  • Immunotherapy
  • Recurrence

Interventions

DRUG

Sintilimab

Patient receives first adjuvant PD-1monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.

DRUG

Lenvatinib

Lenvatinib is initiated orally 2-4 weeks postoperatively for about 6 months.

Sponsors & Collaborators

  • Chen Xiaoping

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2024-04-30
Completion
2025-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06461936 on ClinicalTrials.gov